CARDIOVASCULAR: Rapid Genotype Assay for Individualized Warfarin Dosing

enMarch 25, 2007

Audio Medica News - Medical News Interviews

What was the main topic of the podcast episode?

Summarise the key points discussed in the episode?

Were there any notable quotes or insights from the speakers?

Which popular books were mentioned in this episode?

Were there any points particularly controversial or thought-provoking discussed in the episode?

Were any current events or trending topics addressed in the episode?

What was the main topic of the podcast episode?

Summarise the key points discussed in the episode?

Were there any notable quotes or insights from the speakers?

Which popular books were mentioned in this episode?

Were there any points particularly controversial or thought-provoking discussed in the episode?

Were any current events or trending topics addressed in the episode?

About this Episode

Audio Journal of Cardiovascular Medicine Rapid Genotype Assay for Individualized Warfarin Dosing REFERENCE: Abstract 1020-89, American College of Cardiology New Orleans JEFFREY ANDERSON, University of Utah, Salt Lake City COMMENT: DOUGLAS ZIPES, University of Indiana, Indianapolis The hope of refining treatments for cardiovascular disease by genotyping patients to detect individual sensitivities to particular medical therapies was brought a step closer at the ACC meeting in New Orleans by results from a study using a rapid genothype test. Jeffrey Anderson told Peter Goodwin about the assay they've been investigating which indicates required dosing of warfarin.

Recent Episodes from Audio Medica News - Medical News Interviews

ONCOLOGY: Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma

Audio Journal of Oncology, February 26th, 2008 Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma MARTIN DREYLING, University Hospital Grosshaden, Munich REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.

Audio Medica News - Medical News Interviews

enFebruary 29, 2008

ONCOLOGY: "Total Therapy" Possible Cure For Multiple Myeloma?

Audio Journal of Oncology, February 26th, 2008 "Total Therapy" Possible Cure For Multiple Myeloma? BART BARLOGIE, University of Arkansas, Little Rock REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 A treatment known as "total therapy" could cure many patients with multiple myeloma, conference-goers have just heard. The targeted drugs thalidomide and bortezomib, coupled with tandem autologous transplants, are used by Arkansas-based Bart Barlogie. In Paris he told Peter Goodwin about their success.

Audio Medica News - Medical News Interviews

enFebruary 29, 2008

ONCOLOGY: Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon

Audio Journal of Oncology, February 26th, 2008 Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 Multiple myeloma may soon be considered a chronic disease with cure on the horizon, thanks to an array of novel therapies which are turning prospects around for this malignancy. So said Kenneth Anderson at the European meeting in Paris. He explained to Peter Goodwin how a number of molecular and other therapies are changing the prospects for this disease.

Audio Medica News - Medical News Interviews

enFebruary 27, 2008

MEDICINE: Meta-Analysis Proves Statins Help Patients With Diabetes

Audio Journal of Medicine, January 11th, 2008 Meta-Analysis Proves Statins Help Patients With Diabetes COLIN BAIGENT, Oxford University REFERENCE: Lancet 371:117 January 11, 2008 Statins were foiund to cut cardiovascular event rates by a fifth among patients with both Type I and Type II diabetes in a meta-analysis of 18 000 patients from Oxford University in England and the University of Sydney in Australia. Peter Goodwin asked the lead UK investigator, Colin Baigent, about the findings and their implications.

Audio Medica News - Medical News Interviews

enJanuary 11, 2008

MEDICINE: Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability

Audio Journal of Medicine, January 4th, 2008 Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability PETER TYRER, Imperial College, W6 8RP London REFERENCE: Lancet 371:57 January 5, 2008 A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients who have intellectual disability presenting with a syndrome commonly labelled as "aggressive challenging behaviour" has shown that the anti-psychotic medicines gave no benefit. Peter Goodwin met up with Professor Peter Tyrer at London's Imperial College to ask him about the study.

Audio Medica News - Medical News Interviews

enJanuary 04, 2008

ONCOLOGY: New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer

Audio Journal of Oncology, December 15th, 2007 Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007 New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer JOSE BASELGA, Vall d’Hebron Hospital, Barcelona REFERENCE: ABSTRACT 2066 RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.

Audio Medica News - Medical News Interviews

enDecember 15, 2007

ONCOLOGY: ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

Audio Journal of Oncology, December 15th, 2007 Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007 ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up JACK CUZICK, Wolfson Institute of Preventive Medicine, London REFERENCE: ABSTRACTS 41, 2069, 2071 New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.

Audio Medica News - Medical News Interviews

enDecember 15, 2007

ONCOLOGY: Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

Oncology, December 13th, 2007 Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007 Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide STEPHEN JONES, US Oncology Research, Houston REFERENCE: ABSTRACT 12 Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.

Audio Medica News - Medical News Interviews

enDecember 14, 2007

breast cancer survival

AACR In New Partnership For San Antonio Breast Cancer Symposium

Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007 AACR In New Partnership For San Antonio Breast Cancer Symposium MARGARET FOTI, American Association for Cancer Research, Philadelphia The San Antonio Breast Cancer Symposium will, in the future, be presented jointly by the Cancer Therapy and Research Center at the University of Texas Health Science Center, Baylor College of Medicine, and the American Association for Cancer Research. Peter Goodwin found out more on this new collaboration from Margaret Foti, CEO of the American Association for Cancer Research in Philadelphia.

Audio Medica News - Medical News Interviews

enDecember 14, 2007

iphone

cancer research

health science center

breast-cancer

college of medicine

ONCOLOGY: Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

Audio Journal of Oncology, December 11th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma? CHRISTIAN GEISLER, Rigshospitalet, Copenhagen REFERENCE: ABSTRACT LB1, ASH 2007 Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy approach - from Christian Geisler of Rigshospitalet in Copenhagen.

Audio Medica News - Medical News Interviews

enDecember 11, 2007

Ask this episode Anything

What was the main topic of the podcast episode?

Summarise the key points discussed in the episode?

Were there any notable quotes or insights from the speakers?

Which popular books were mentioned in this episode?

Were there any points particularly controversial or thought-provoking discussed in the episode?

Were any current events or trending topics addressed in the episode?